Citidaron® Overview
Get an overview of the safety data and tolerability of Citidaron.
Safety Profile
Get an overview of the safety data and tolerability of Citidaron.
Prescribing Considerations
Get an overview of the safety data and tolerability of Citidaron.
Citidaron® Overview
Get an overview of the safety data and tolerability of Citidaron.
Safety Profile
Get an overview of the safety data and tolerability of Citidaron.
Prescribing Considerations
Get an overview of the safety data and tolerability of Citidaron.
Citidaron® Overview
Get an overview of the safety data and tolerability of Citidaron.
Safety Profile
Get an overview of the safety data and tolerability of Citidaron.
Prescribing Considerations
Get an overview of the safety data and tolerability of Citidaron.
Our sustainability approach is integral to our business strategy.
Additionally, by attracting and retaining top-tier talent, we are committed to building on our strong reputation and positioning ourselves as leaders within the SME segment of the market.
Consilient Health is a privately owned pharmaceutical company.
Being a sustainable business underpins everything we do at Consilient Health. We focus on people, being responsible and remaining a competitive business.
Our sustainability approach is integral to our business strategy.
Our sustainability approach is a core component of our business strategy. By engaging with both internal and external stakeholders and incorporating environmental, social, and governance (ESG) factors into our decision-making processes, we aim to enhance long-term company value. Additionally, by attracting and retaining top-tier talent, we are committed to building on our strong reputation and positioning ourselves as leaders within the SME segment of the market.
Have a partnership opportunity for us?
Contact with us on LinkedIn
Locations
Our Headquarters are in Dublin, Ireland. Our European Operational
hub is in London, UK and our Nordic regional office is in Uppsala,
Sweden. We have partnerships in Benelux and Spain.
Locations
Our Headquarters are in Dublin, Ireland. Our European Operational
hub is in London, UK and our Nordic regional office is in Uppsala,
Sweden. We have partnerships in Benelux and Spain.
Locations
Our Headquarters are in Dublin, Ireland. Our European Operational
hub is in London, UK and our Nordic regional office is in Uppsala,
Sweden. We have partnerships in Benelux and Spain.
Citidaron should be taken with a suitable amount of water according to the following dosage schedule.
| Days of treatment | Recommended dosing | Maximum daily dose |
|---|---|---|
| Day 1 – 3 | 1 tablet every 2 hours | 6 tablets |
| Day 4 – 12 | 1 tablet every 2.5 hours | 5 tablets |
| Day 13 – 16 | 1 tablet every 3 hours | 4 tablets |
| Day 17 – 20 | 1 tablet every 5 hours | 3 tablets |
| Day 21 – 25 | 1-2 tablets a day | to 2 tablets |
Citidaron should be taken with a suitable amount of water according to the following dosage schedule.
| Days of treatment | Recommended dosing | Maximum daily dose |
|---|---|---|
| Day 1 – 3 | 1 tablet every 2 hours | 6 tablets |
| Day 4 – 12 | 1 tablet every 2.5 hours | 5 tablets |
| Day 13 – 16 | 1 tablet every 3 hours | 4 tablets |
| Day 17 – 20 | 1 tablet every 5 hours | 3 tablets |
| Day 21 – 25 | 1-2 tablets a day | to 2 tablets |
The ten principles of the United Nations global compact.
Human rights
1
Businesses should support and respect the protection of internationally proclaimed human rights; and
2
Make sure that they are not complicit in human rights abuses.
Labour
3
Businesses should uphold the freedom of association and the effective recognition of the right to collective bargaining;
4
The elimination of all forms of forced and compulsory labour;
5
The effective abolition of child labour; and
6
The elimination of discrimination in respect of employment and occupation.
Environment
7
Businesses should support a precautionary approach to environmental challenges;
8
Undertake initiatives to promote greater environmental responsibility; and
9
Encourage the development and diffusion of environmentally friendly technologies.
Anti-corruption
10
Businesses should work against corruption in all its forms, including extortion and bribery.
One Pack, One Prescription
Simplifies prescribing and dispensing, supporting immediate patient access while reducing administrative burden.
25 Day Treatment Course
A short, structured treatment designed to support patients through the critical early phase of quitting.
GMS Reimbursed
An accessible prescription option for those motivated to quit.
50+ Years in Quit Support
A valuable alternative for patients seeking to quit without nicotine or long-term therapies
One Pack, One Prescription
Simplifies prescribing and dispensing, supporting immediate patient access while reducing administrative burden.
25 Day Treatment Course
A short, structured treatment designed to support patients through the critical early phase of quitting.
GMS Reimbursed
An accessible prescription option for those motivated to quit.
50+ Years in Quit Support
A valuable alternative for patients seeking to quit without nicotine or long-term therapies
Updates
Sustainability
Business
Consilient Health will cease the distribution of the Theramex range of medicines in Ireland
10 Oct 2025
Consilient Health wish to announce that as of the 1st of September, Consilient Health will no longer distribute the Theramex range (...
Introducing Yanae®: A New Copper IUD
10 Oct 2025
Consilient Health is excited to announce the upcoming launch of Yanae® in Ireland, (...
Menopause Workplace Excellence Silver Accreditation
10 Oct 2025
Following on from our recognition the previous month at the Menopause Workplace Excellence Awards, (...
Recognition for Consilient Health Ireland at Menopause Workplace Excellence Awards 2024
10 Oct 2025
Consilient Health Ireland is proud to be recognised as a leading employer in supporting menopausal and perimenopausal women (...
Consilient Health are Great Place to Work® Ireland certified for two consecutive years
10 Oct 2025
Consilient Health is delighted to share that we are Great Place to Work® Ireland certified (...
Consilient Health announce the re-launch of Mysimba
10 Oct 2025
Consilient Health are pleased to announce the re-launch of Mysimba, a prescription medicine which can help your patients (...
Consilient Health Ireland Wins Guaranteed Irish Award for the Pharmaceutical and MedTech Sector
10 Oct 2025
On Thursday the 21st of March 2024, Consilient Health Ireland won the Guaranteed Irish Business Awards (...
Meet our people
Toby Kavanagh
National Sales Manager and Pharmacy Lead
Regina Brady
Primary Care Specialist Bone Health and Menopause Territory: West of Ireland, Cork and Kerry
Gemma Fitzsimons
Primary Care Specialist Bone Health and Menopause. Territory: South Dublin, Waterford and Cork
Siobhan Maguire
Primary Care Specialist Bone Health and Menopause.Territory: North Dublin and Donegal
Deirdre Kelly
Country Manager, Ireland and Malta
Bella Delic
Commercial Excellence and Marketing Executive
Emma Gibbs
Marketing Executive
Susan Aughney
Marketing Manager Bone Health, Menopause and Weight Management
Bronagh Lambe
Marketing Manager Women’s Health
Feidhlim Dervin
Marketing Manager Smoking Cessation
Contact Us
"*" indicates required fields
Frequently Asked Questions
Is cytisine the same as cytisinicline?
Yes, cytisine and cytisinicline are the same. Although the generic name (INN) Cytisine has been widely used for many decades, more recently the WHO proposed changing this to cytisinicline. You may therefore find it listed under “cytisine”, “cytisinicline”, or both.
Are dosing instructions printed on tablet foil strip?
Yes, cytisine and cytisinicline are the same. Although the generic name (INN) Cytisine has been widely used for many decades, more recently the WHO proposed changing this to cytisinicline. You may therefore find it listed under “cytisine”, “cytisinicline”, or both.Yes, cytisine and cytisinicline are the same. Although the generic name (INN) Cytisine has been widely used for many decades, more recently the WHO proposed changing this to cytisinicline. You may therefore find it listed under “cytisine”, “cytisinicline”, or both.
Why are there age restrictions on Citidaron in those over 65 or under 18?
Yes, cytisine and cytisinicline are the same. Although the generic name (INN) Cytisine has been widely used for many decades, more recently the WHO proposed changing this to cytisinicline. You may therefore find it listed under “cytisine”, “cytisinicline”, or both.
Is there a specific degree of renal or hepatic impairment at which Citidaron should not be used?
Yes, cytisine and cytisinicline are the same. Although the generic name (INN) Cytisine has been widely used for many decades, more recently the WHO proposed changing this to cytisinicline. You may therefore find it listed under “cytisine”, “cytisinicline”, or both.
What is considered a “recent” myocardial infarction or stroke?
Yes, cytisine and cytisinicline are the same. Although the generic name (INN) Cytisine has been widely used for many decades, more recently the WHO proposed changing this to cytisinicline. You may therefore find it listed under “cytisine”, “cytisinicline”, or both.
What if a patient forgets to take a tablet?
Yes, cytisine and cytisinicline are the same. Although the generic name (INN) Cytisine has been widely used for many decades, more recently the WHO proposed changing this to cytisinicline. You may therefore find it listed under “cytisine”, “cytisinicline”, or both.Yes, cytisine and cytisinicline are the same. Although the generic name (INN) Cytisine has been widely used for many decades, more recently the WHO proposed changing this to cytisinicline. You may therefore find it listed under “cytisine”, “cytisinicline”, or both.
Yes, cytisine and cytisinicline are the same. Although the generic name (INN) Cytisine has been widely used for many decades, more recently the WHO proposed changing this to cytisinicline. You may therefore find it listed under “cytisine”, “cytisinicline”, or both.
Our vision & values
Creating Value for all our stakeholders by bringing licensed pharmaceutical products to market. Our core values are teamwork, working in partnership and having an intelligent approach
“Our established business development
process enables us to promptly review partnering opportunities and provide a rapid and
transparent decision-making process.”
Our established business development
process enables us to promptly review partnering opportunities and provide a rapid and transparent decision-making process.
Adverse events should be reported. Reporting forms and information are available from HPRA Pharmacovigilance on the HPRA website www.hpra.ie. Adverse events should also be reported to Consilient Health at drugsafety@consilienthealth.com or 012057766.
The information on this website is intended for Health Care Professional who practice in the Republic of Ireland only
Healthcare professionals are asked to report any suspected adverse reactions. To report an adverse event or a product complaint about a Consilient Health medicine, please contact Consilient Health at drugsafety@consilienthealth.com or 012057766
Adverse events and product complaints may also be reported to the Health Products Regulatory Authority. Reporting form and information can be found at www.hpra.ie then click on “report an issue”.
References
- HSE (Health Service Executive). Tobacco Free Ireland Annual Report 2022. Available at: https://www.hse.ie/eng/about/who/tobaccocontrol/tfi-annual-report-2022.pdf [Accessed: July, 2025].
- Department of Health. Economic and social cost of smoking in Ireland. Dublin: Department of Health, 2022. Available at: https://www.gov.ie/en/publication/5d2c8-economic-and-social-cost-of-smoking-in-ireland/ [Accessed: July, 2025].
- Ipsos B&A. (2023) Healthy Ireland survey 2023 – summary report. Dublin: Healthy Ireland, Department of Health. Available at: https://www.drugsandalcohol.ie/39977/ (Accessed July 2025)
- Healthy Ireland Survey 2021. Summary Report. Department of Health, 2021. Available at: https://www.gov.ie/en/publication/9ef45-healthy-ireland-survey-2021/ [Accessed: July, 2025].
- HSE Smoking facts and figures. Availabel at https://www2.hse.ie/living-well/quit-smoking/reasons-to-quit/facts-and-figures/ (Accessed July 2025)
- NHS Inform. Benefits of stopping smoking. Available at https://www.nhsinform.scot/healthy-living/stopping-smoking/reasons-to-stop/benefits-of-stopping-smoking/. Accessed July 2025.
About us
We are a mid-sized pharmaceutical company with a
strong heritage of commercialising
differentiated and niche products in complex markets.
Explore strategic partnerships and grow our pipeline together
Experience and past partnerships.
Since the beginning, we have built and nurtured a range of long-term, mutually beneficial partnerships with pharmaceutical developers and manufacturers. These collaborations span from small, innovative biotech firms to large, publicly listed companies.
Since the beginning, we have built and nurtured a range of long-term, mutually beneficial partnerships with pharmaceutical developers and manufacturers. These collaborations span from small
Experience and past partnerships.
At Consilient Health, sustainability is at the heart of everything we do.As proud participants in the UN Global Compact, we align with the goldstandard for measuring and reducing carbon emissions. While ourcommitment to sustainability is driven by a deep belief in doing what is right, it is increasingly essential to meet and exceed sustainability benchmarks to maintain robust partnerships and resilient supply chains.
Since the beginning, we have built and nurtured a range of long-term, mutually beneficial partnerships with pharmaceutical developers and manufacturers. These collaborations span from small
CORP-CH-1675 May 2026
Driven by developing strong partnerships.
Founded in 2005, our success has been driven by developing strong partnerships with pharmaceutical companies, ensuring market access, and effectively marketing and distributing their prescription healthcare products in the UK and Europe. We carefully evaluate and prioritise products that are differentiated and have the potential to address clear unmet clinical needs.
As an independent, privately held, and profitable business, we are able to make swift decisions and have the resources and expertise to explore innovative solutions that meet the needs of patients, prescribers, payers, and partners.
Our focused and dedicated approach is evidenced by numerous successful product launches with a range of partners, navigating various regulatory environments. With a strong financial foundation and commercial focus, we are well-positioned to invest in long-term collaborations and expand our portfolio while supporting the needs of our partners.
End-to-end solutions across compliance, access, logistics, and sales.
We are experienced and innovative commercialisation experts for the UK and European market, offering comprehensive capabilities that span regulatory affairs, market access, supply chain management, distribution, medical affairs, marketing, and sales, all underpinned by a commitment to quality and compliance.
Our partners, typically focused on developing and manufacturing medicines andhealthcare solutions, may lack the physical presence, expertise, or resources to commercialise their products in the UK or Europe. Consilient Health provides the necessary capabilities to extend their geographic reach, optimise revenue, and minimise risk.
As a mid-sized pharmaceutical company, we do not engage in research,
development, or manufacturing. Instead, our experienced management team is dedicated to advancing our partners’ products and brands. We deliver innovative marketing strategies informed by strategic insights and local market knowledge, ensuring effective commercialisation. We prioritise transparent communication, fostering long-term, mutually beneficial partnerships.
Partner With Us
We are continuously seeking new strategic partnerships and alliances to further strengthen, diversify and expand our pipeline.
By collaborating with partners, we identify opportunities and unlock the potential of products that offer the greatest benefit to patients and healthcare professionals.
Our Medicines
We provide high quality medicines in formulations and presentations that meet clinical and patient needs.
Explore strategic partnerships and grow our pipeline together
Working in Partnership
Consilient Health is invested in working with healthcare and pharmaceutical Industry stakeholders. This is part of our commitment to bring high quality medicines and innovative solutions to Irish healthcare professionals and patients.
Industry bodies we collaborate with
- www.hpra.ie
- www.hse.ie
- www.medicinesforeurope.com
- www.thepmi.com
Consilient Health Ireland is delighted to be a founding member of the Alliance of Medicines for Ireland trade association (MFI). Further information on MFI can be found at www.medicinesforireland.ie
Our Partners
Consilient Health has an established track record in partnering with globally recognised research based pharmaceutical companies.
Some of our commercial partners include:
- Italfarmaco
- Aflofarm
- Currax Pharmaceuticals (MAH: Orexigen)
- SMB Laboratories
With the expertise of our Irish team, we offer partners local insight and understanding to optimise the commercial success of their medicines.
Sustainability at Consilient Health
At Consilient Health, sustainability is at the heart of everything we do.As proud participants in the UN Global Compact, we align with the gold standard for measuring and reducing carbon emissions. While our commitment to sustainability is driven by a deep belief in doing what is right, it is increasingly essential to meet and exceed sustainability benchmarks to maintain robust partnerships and resilient supply chains.
At Consilient Health, sustainability is at the heart of everything we do. As proud participants in the UN Global Compact, we align with the gold standard for measuring and reducing carbon emissions. While our commitment to sustainability is driven by a deep belief in doing what is right.
CORP-CH-1675 May 2026
Citidaron®
Citidaron® is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking.1
The treatment goal of Citidaron® is the permanent cessation of the nicotine-containing products use.1
About Citidaron
CITIDARON® is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking.1 The treatment goal of CITIDARON® is the permanent cessation of the nicotine-containing products use.1
Citidaron does not contain nicotine and has a favourable tolerability profile.
About Citidaron
Cytisinicline is a partial agonist of the α4β2 nicotinic acetylcholine receptor.1
Cytisinicline competes with nicotine for the same receptors and gradually displaces nicotine due to its stronger binding. It has lower ability to stimulate nicotinic receptors.1
How Nicotine Drives Addiction
Nicotine binds to nicotinic acetylcholine receptors on dopamine neurons in the brain’s ventral tegmental area. This triggers rapid neuronal firing and causes a surge of dopamine release in the nucleus accumbens — the brain’s reward centre.
This dopamine release reinforces the pleasurable effects of smoking, contributing to nicotine dependence and addiction.
Citidaron® Tolerability1
Mild to moderate adverse reactions have been observed with the use of Citidaron®, most frequently concerning the gastrointestinal tract.
Clinical trials and prior experience indicate that the majority of adverse reactions occurred at the beginning of Citidaron® therapy and resolved during treatment.
Citidaron® Prescribing Considerations1
CITIDARON® is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. The treatment goal of CITIDARON® is the permanent cessation of the nicotine-containing products use. Please refer to the full Summary of Product Characteristics before prescribing CITIDARON®
CITIDARON® is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. The treatment goal of CITIDARON® is the permanent cessation of the nicotine-containing products use.
CITIDARON® is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. The treatment goal of CITIDARON® is the permanent cessation of the nicotine-containing products use. Please refer to the full Summary of Product Characteristics before prescribing CITIDARON®
Other Key Safety Considerations
- Depressed mood may be a symptom of nicotine withdrawal. Clinicians should be aware of the possible emergence of serious neuropsychiatric symptoms in patients attempting to quit smoking with and without treatment.
- Patients should be aware that the simultaneous administration of Citidaron and smoking or use of products containing nicotine could lead to aggravated adverse reactions of nicotine.
- Women of childbearing potential must use highly effective contraception while taking Citidaron. It is currently unknown whether Citidaron may reduce the effectiveness of systemically acting hormonal contraceptives, and therefore women using systemically acting hormonal contraceptives should add a second barrier method.
- There is no clinical experience of Citidaron in patients with renal or hepatic impairment, therefore Citidaron is not recommended for use in this patient population.
- Citidaron is not recommended for use in patients <18 years and patients >65 years
Taking Citidaron®1
Citidaron is administered orally over a 25-day treatment course, with one pack containing 100 tablets, sufficient for the entire course1. Smoking should not be continued during the treatment as this may aggravate adverse reactions. Smoking should be stopped no later than on the 5th day of treatment1.
In case of treatment failure, the treatment should be discontinued and may be resumed after 2 to 3 months.
Citidaron® Dosing Guide1
Citidaron Dosing Guide is available to download below or from the Consilient Health website. Please Contact Us if you would like copies of these leaflets
- Digital: (interactive) dosing guide and patient leaflet
- Easy to print dosing guide and patient leaflet
Smoking cessation - A priority in Ireland
Every week, over 100 people die and over 1,000 people are hospitalized in Ireland from smoking-related illness1. Smoking and its effects place a large pressure on healthcare resources. In 2019, 44,000 hospitalisations were estimated to be attributed to smoking2
-Smoking contributed to2:
- 20% of respiratory disease hospitalisations
- 10% of circulatory disease hospitalisations
- 10% of circulatory disease hospitalisations
The burden of smoking
Although there was a steady decline in the prevalence of smoking in Ireland from 23% in 2015 to 17% in 2019, this rate has now increased slightly. Across Ireland in 2023, 18% of the population were smokers, with 14% daily smokers and 4% smoked occasionally3
83% of smokers regret starting smoking – they would not smoke if they had the choice again4
Smoking can5:
- Take 10 to 15 quality years off your life
- Cause cancer, heart attacks, stroke, lung disease, blindness, diabetes and many other diseases
- reduce fertility for both women and men and makes it harder to start a family
- Lead to ectopic pregnancy, miscarriage and stillbirth if you smoke during pregnancy
- Have a negative effect on mental health
- Be an expensive habit – smoking 20 cigarettes a day adds up to over €5,000 a year
About Citidaron®
Citidaron is your companion in this journey to quit smoking. Designed specifically to aid in the reduction and eventual cessation of nicotine cravings, Citidaron facilitates a smoother transition away from nicotine dependence. By following the prescribed schedule, you’ll gradually lessen your reliance on nicotine, thanks to Citidaron’s active ingredient, cytisine, which eases withdrawal symptoms by acting on nicotine receptors in a way similar to nicotine but without its harmful effects.
It’s important to stick to the treatment plan and remember that Citidaron is most effective when combined with your commitment to stop smoking. Together, we can make your goal of becoming smoke-free a reality.1,2
